Finoriq research workspace
ADIAL PHARMACEUTICALS, INC. (ADIL) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for ADIAL PHARMACEUTICALS, INC. (ADIL).
Company Snapshot
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- Company
- ADIAL PHARMACEUTICALS, INC. (ADIL)
- Ticker
- ADIL
- Market Cap
- $5.9M
- Latest Price
- $2.73
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.